These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Antipyretic effect of tenoxicam and paracetamol in febrile children. Similä S; Kylmämaa T Drugs Exp Clin Res; 1985; 11(10):731-4. PubMed ID: 3915461 [TBL] [Abstract][Full Text] [Related]
25. Mechanism of action of drugs for treating inflammation and arthritis. Lombardino JG Eur J Rheumatol Inflamm; 1983; 6(1):24-35. PubMed ID: 6345165 [TBL] [Abstract][Full Text] [Related]
26. Rat neutrophil activation and effects of lipoxygenase and cyclooxygenase inhibitors. Ward PA; Sulavik MC; Johnson KJ Am J Pathol; 1984 Aug; 116(2):223-33. PubMed ID: 6087668 [TBL] [Abstract][Full Text] [Related]
27. Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Martin WJ; Kachel DL Am Rev Respir Dis; 1985 Apr; 131(4):544-7. PubMed ID: 2986500 [TBL] [Abstract][Full Text] [Related]
28. An overview of isoxicam: a new nonsteroidal anti-inflammatory drug. Downie WW Singapore Med J; 1985 Feb; 26(1):29-33. PubMed ID: 3895443 [No Abstract] [Full Text] [Related]
29. [Evaluation of the efficacy and tolerance of a new non-steroidal anti-inflammatory agent, isoxicam]. Marcolongo R; Giordano N; Fioravanti A; Frati E; Mariani AM; Casini A Clin Ter; 1984 Dec; 111(6):513-9. PubMed ID: 6525811 [No Abstract] [Full Text] [Related]
30. Influence of nonsteroidal anti-inflammatory agents on lapine articular chondrocyte growth in vitro. Kirkpatrick CJ; Mohr W; Mildfeuer A; Haferkamp O Z Rheumatol; 1983; 42(2):58-65. PubMed ID: 6880403 [TBL] [Abstract][Full Text] [Related]
31. The analgetic properties of piroxicam in animals and correlation with experimentally determined plasma levels. Milne GM; Twomey TM Agents Actions; 1980 Apr; 10(1 Pt 2):31-7. PubMed ID: 7386306 [TBL] [Abstract][Full Text] [Related]
32. Hepatitis induced by isoxicam. Ollagnon HO; Perpoint B; Decousus H; Ollagnier M; Queneau P Hepatogastroenterology; 1986 Jun; 33(3):109. PubMed ID: 2943659 [No Abstract] [Full Text] [Related]
33. Antiinflammatory activity and bioavailability of percutaneous piroxicam. Schiantarelli P; Cadel S; Acerbi D; Pavesi L Arzneimittelforschung; 1982; 32(3):230-5. PubMed ID: 7200781 [TBL] [Abstract][Full Text] [Related]
34. Ro 12-0068 (tenoxicam) in the treatment of extra-articular inflammatory processes. Fiszman P; Perpétuo JB; Sidi A Eur J Rheumatol Inflamm; 1985; 8(1):15-20. PubMed ID: 3915883 [TBL] [Abstract][Full Text] [Related]
36. Acceleration of the elimination of tenoxicam by cholestyramine in the dog. Guentert TW; Schmitt M; Defoin R J Pharmacol Exp Ther; 1986 Jul; 238(1):295-301. PubMed ID: 3723402 [TBL] [Abstract][Full Text] [Related]
37. Piroxicam--a literature review of new results from laboratory and clinical studies. Ando GA; Lombardino JG Eur J Rheumatol Inflamm; 1983; 6(1):3-23. PubMed ID: 6345166 [TBL] [Abstract][Full Text] [Related]
39. A double-blind parallel study of tenoxicam and piroxicam in patients with osteoarthrosis. Bird HA; Hill J; Dixon JS; Looi D; Wright V Eur J Rheumatol Inflamm; 1985; 8(1):53-9. PubMed ID: 3915888 [TBL] [Abstract][Full Text] [Related]
40. Endocrine disorders render rats hyporeactive to non-steroidal but not to steroidal anti-inflammatory drugs. Valle CC; Hacad E; Sudo LS; Garcia-Leme J Braz J Med Biol Res; 1985; 18(3):341-7. PubMed ID: 3835984 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]